Protocol No
CVC-CYTOKINETICS-COMET-AF
Staff Member
Jose C Mendez
Phase
III
Summary
This project is being done to to find out if omecamtiv mecarbil reduces the risk of heart failure-related events and deaths, heart transplant, and strokes in heart failure patients with reduced ejection fraction.
Objective
Trial to Assess Omecamtiv Mecarbil in Patients with HF with Severely Reduced Ejection Fraction
Status
OPEN TO ACCRUAL
Categories